COMMENTARY: Ottawa’s management of COVID-19 vaccine file leaves much to be desired - Global News | Canada News Media
Connect with us

Business

COMMENTARY: Ottawa’s management of COVID-19 vaccine file leaves much to be desired – Global News

Published

 on


Canadians are understandably feeling anxious and impatient when it comes to the question of vaccine availability.

After all, Canada is falling behind numerous other countries when it comes to overall percentage of the population that’s been vaccinated, we’ve seen disruptions in the delivery of the two vaccines that have been approved for use here, and we’re hearing all sorts of protectionist rumblings that could further disrupt — or block — vaccine shipments.

At the same time, though, there is some potential development that might help improve Canada’s situation: Health Canada is said to be close to a decision on whether to approve AstraZeneca’s vaccine and this past week has delivered some encouraging news with regard to the vaccines developed by two other companies with whom Canada has signed purchase agreements (Novavax and Johnson & Johnson).

How this all plays out remains to be seen, but much of Canada’s strategy at this point involves hoping for the best. To a large extent we are at the mercy of numerous outside forces and we shouldn’t lose sight of just how enormous an undertaking it is to develop, manufacture, distribute, and administer hundreds of millions of vaccines. Some tempering of expectations is reasonable.

Story continues below advertisement

Read more:
Domestic vaccine-makers want more help from Ottawa: ‘There’s been a real lack of leadership’

At the same time, however, “good enough” isn’t good enough. It’s fair to wonder whether the government has done all it possibly can to strengthen Canada’s position. It’s also more than fair to review the decisions that were made (or not made) over the last 12 months and to what extent they weakened our position.

For starters, a significant factor in Canada’s vulnerability is none of the vaccines we’ve approved or signed purchase agreements for are actually made in this country. It’s not a coincidence that the major companies we’re now counting on to produce and deliver vaccines to us have chosen to set up shop elsewhere. While the current government bears some responsibility for this state of affairs, it’s a problem with roots that run far deeper than the past 12 months.

However, it is fair to wonder to what extent the government has sought to maximize the few advantages we have in this area.

The company Sanofi, for example, has a manufacturing facility in Ontario. Now that Sanofi has shelved its own plans for a coronavirus vaccine, they’ve agreed to partner with Pfizer to help add to the global supply of the latter’s vaccine. It’s unclear whether that endeavour will include the Ontario plant, but it seems odd that the government would just play the role of spectator in all of this, considering how vital any sort of domestic production might be right now.

Story continues below advertisement

Furthermore, there’s the question of how the government has treated upstart Canadian pharmaceutical and biotech companies. Developing a home-grown advantage should have been a top priority.

Two companies — Providence Therapeutics and Entos Pharmaceuticals — have both voiced their frustrations at how difficult it was to get Ottawa’s attention last year and how detrimental that lack of support was in not just developing their respective vaccines but also their production capability. Providence now has their vaccine candidate into phase 1 clinical trials and Entos will follow suit in the coming weeks, but both say they would be much further along had there been more meaningful federal support.

And, of course, there’s the question of the ill-fated and almost certainly ill-advised partnership with Chinese pharmaceutical company CanSino, which was announced with much fanfare last May by Prime Minister Trudeau.

Story continues below advertisement

Read more:
Moderna joins Pfizer in cutting back on vaccine deliveries to Canada next week

We have subsequently learned, though, that this deal went sideways very quickly — just days after the government first announced it, in fact. However, it wasn’t until August that the government publicly acknowledged that the agreement had fallen apart and would not proceed. That’s the same month, by the way, that the government announced it had signed purchase agreements with Pfizer and Moderna.

Putting aside the question of how much trust and faith we should have had in the Chinese government to begin with — especially on something as important as this — it’s fair to wonder how distracted the government was in trying to preserve this deal and to what extent it distracted from or delayed other efforts to secure vaccines expand our domestic capabilities.

Dwelling on the past doesn’t fix the problems in the here and now, but it all points to valid questions about how the government has been and is handling what is arguably the most important issue on the government’s plate at the moment.

Better is always possible, but even more so if mediocre is the starting point.

Rob Breakenridge is host of ‘Afternoons with Rob Breakenridge’ on Global News Radio 770 Calgary and a commentator for Global News.

Advertisement

© 2021 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version